Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis
Boster A, Bartoszek MP, O’Connell C, Pitt D, Racke M. Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis. Therapeutic Advances In Neurological Disorders 2011, 4: 319-332. PMID: 22010043, PMCID: PMC3187678, DOI: 10.1177/1756285611422108.Peer-Reviewed Original ResearchWhat happens when natalizumab therapy is stopped?
Schaaf SM, Pitt D, Racke MK. What happens when natalizumab therapy is stopped? Expert Review Of Neurotherapeutics 2011, 11: 1247-1250. PMID: 21864070, DOI: 10.1586/ern.11.109.Peer-Reviewed Original ResearchMS disease activityDisease activityActive diseaseNatalizumab cessationTreatment interruptionMultiple sclerosisBaseline levelsSimilar disease activityProgressive multifocal leukoencephalopathyNatalizumab exposureNatalizumab therapyNatalizumab treatmentMultifocal leukoencephalopathyMS patientsMRI measuresMS treatmentEvidence of reboundDiseaseElimination kineticsNatalizumabIntegrin antagonistsTreatmentPatientsCessationLeukoencephalopathy